INVITATION
Advanced Accelerator Applications, a Novartis Company - Elucidate metastatic prostate cancer targets with radioligand therapy and molecular profiling: Advancing precision medicine in prostate cancer
INVITATION
F. Hoffmann-La Roche Ltd. - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer